April 16 (Reuters) - Alkermes Plc:
* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER
* ALKERMES PLC - FDA ACTION EXPECTED BY JAN. 31, 2019
* ALKERMES - ALKS 5461 NDA FILING BASED ON RESULTS FROM A CLINICAL EFFICACY AND SAFETY PACKAGE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
